Fc ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå : ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø - °³º¯ À¯Çüº°, Ä¡·á À¯Çüº°, Ä¡·á ¿µ¿ªº°, Åõ¿© °æ·Îº°, ÁÖ¿ä Áö¿ªº°
Fc and Glycoengineered Antibodies Market : Industry Trends and Global Forecasts - Distribution by Type of Engineering, Type of Therapy, Therapeutic Area, Route of Administration and Key Geographical Regions
»óǰÄÚµå : 1762535
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 293 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,650,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 9,699,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 14,688,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 24,943,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Fc ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå : °³¿ä

¼¼°èÀÇ Fc ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå ±Ô¸ð´Â ¿ÃÇØ 388¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº 2035³â±îÁöÀÇ ¿¹Ãø ±â°£ Áß À¯¸®ÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­¿¡¼­´Â ½ÃÀå ±Ô¸ð¿Í ±âȸ ºÐ¼®À» ´ÙÀ½°ú °°Àº ¸Å°³ º¯¼ö·Î ±¸ºÐÇÕ´Ï´Ù.

¼öÁ¤ À¯Çü

Ä¡·á À¯Çü

Ä¡·á ¿µ¿ª

Åõ¿© °æ·Î

ÁÖ¿ä Áö¿ª

Fc ¹× ´ç¼â º¯Çü Ç×ü ½ÃÀå : ¼ºÀå ¹× µ¿Çâ

100°³¿¡ °¡±î¿î ¸ð³ëŬ·Î³Î Ç×ü°¡ ½ÂÀεǰí 550°³ ÀÌ»óÀÇ ºÐÀÚ°¡ ÀÓ»ó ÆÄÀÌÇÁ¶óÀο¡ ÀÖ´Â »óȲ¿¡¼­ Ç×ü ±â¹Ý ¾à¸®ÇÐÀû °³ÀÔÀº ¹ÙÀÌ¿ÀÀǾàǰ »ê¾÷¿¡¼­ °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÐ¾ß Áß Çϳª°¡ µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ Ç×ü Ä¡·áÁ¦ ¾÷°è¿¡¼­´Â ÃÖ±Ù ¼ö³â°£ Fc(Fragment Crystallization) ¿µ¿ªÀ» º¯ÇüÇÏ¿© °³¹ßµÈ Àΰø Ç×ü°¡ Å« °ü½ÉÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Ç×üÀÇ Fc À¶ÇÕ ´Ü¹éÁú¿¡¼­ ´ç¼â°øÇÐ Ç×ü, ´Ü¹éÁú ¿£Áö´Ï¾î¸µ, ¾ÆÀ̼ÒÀ¯Çü-Ű¸Þ¸®Áò µîÀÇ º¯ÇüÀº Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¼¼Æ÷µ¶¼º(ADCC), º¸Ã¼ ÀÇÁ¸¼º ¼¼Æ÷µ¶¼º(CDC), Ç×ü ÀÇÁ¸¼º ¼¼Æ÷Æ÷½Ä(ADCP) Ȱ¼º, ºÐÀÚ ¹Ý°¨±â µî ´Ù¾çÇÑ ÀÌÆåÅÍ ±â´ÉÀ» °­È­ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ ÀϺΠFc º¯Çü ±â¼úÀº ƯÁ¤ °æ·Î¿¡¼­ ÀÌÆåÅÍ ±â´ÉÀ» ¾ïÁ¦ÇÒ ¼ö ÀÖÀ¸¸ç, Ç×¾ÏÇ×ü °³¹ßÀ» À§ÇØ È°¹ßÈ÷ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù.

Fc and Glycoengineered Antibodies Market-IMG1

ÀÌ ºÐ¾ß¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸ ³ë·ÂÀÇ °á°ú, °¡Áî¹Ù(¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦)¿Í Æ÷Å×·¹Áö¿À(¼¼ÀÚ¸® ÁõÈıº Ä¡·áÁ¦)¶ó´Â µÎ °¡Áö ȹ±âÀûÀÎ ¾à¹°ÀÌ Åº»ýÇß½À´Ï´Ù. ¶ÇÇÑ Margenza, MONJUVI, SKYRIZI µî ¿©·¯ Fcº¯Çü Ç×ü Á¦Ç°µµ Áö³­ ¼ö³â°£ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ÃÖ±Ù¿¡´Â EpcolitamabÀ̶ó´Â À̸§ÀÇ Fc º¯Çü Ç×ü°¡ ¹Ì¸¸¼º ´ë¼¼Æ÷ B¼¼Æ÷ ¸²ÇÁÁ¾ Ä¡·áÁ¦·Î ½ÂÀεǾú½À´Ï´Ù. ¶ÇÇÑ °³¹ß ÆÄÀÌÇÁ¶óÀο¡ ÀÖ´Â ¸î °¡Áö ÀǾàǰµµ ÀÖÀ¸¸ç, ´Ù¾çÇÑ Áß¼Ò Á¦¾à»ç ¹× ´ëÇü Á¦¾à»ç°¡ ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. À¯¸ÁÇÑ ÀÓ»ó °á°ú¿Í ÇöÀç ÁøÇà ÁßÀÎ ±â¼ú °³¹ß·Î ÀÎÇØ Fc º¯Çü Ç×ü ½ÃÀåÀº ÇâÈÄ 10³â°£ ³î¶ó¿î ¼Óµµ·Î ¹ßÀüÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Fc ¹× ´ç¼â º¯Çü Ç×ü ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

ÀÌ º¸°í¼­´Â Fc ¹× ´ç¼â º¯Çü Ç×ü ½ÃÀåÀÇ ÇöȲÀ» Á¶»çÇÏ°í ¾÷°èÀÇ ÀáÀçÀûÀÎ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÕ´Ï´Ù. ÀÌ º¸°í¼­ÀÇ ÁÖ¿ä Á¶»ç °á°ú´Â ´ÙÀ½°ú °°½À´Ï´Ù.

Fc and Glycoengineered Antibodies Market-IMG2
Fc and Glycoengineered Antibodies Market-IMG3

Fc ¹× ´ç¼â º¯Çü Ç×ü ½ÃÀå : ÁÖ¿ä ºÎ¹®

Fc ¹× ´ç¼â º¯Çü Ç×ü ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Fc º¯Çü Ç×ü ºÎ¹®

Fc º¯Çü À¯Çü¿¡ µû¶ó ½ÃÀåÀº Fc º¯Çü Ç×ü¿Í ´ç¼â º¯Çü Ç×ü·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ¼¼°è Fc ¹× ´ç¼â º¯Çü Ç×ü ½ÃÀå¿¡¼­ Fc º¯Çü Ç×ü ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Fc º¯ÇüÀÌ ÀÌÆåÅÍ ±â´ÉÀ» °­È­Çϰí Ä¡·á È¿°ú¸¦ Çâ»ó½ÃŲ´Ù´Â »ç½Ç·Î ÀÎÇØ ÇâÈÄ ¼ö³â°£ º¯ÇÔ¾øÀÌ À¯ÁöµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Ä¡·á À¯Çüº°·Î ½ÃÀåÀº ´Üµ¶¿ä¹ý, º´¿ë¿ä¹ý, ±×¸®°í µÎ °¡Áö ¸ðµÎ·Î ºÐ·ùµË´Ï´Ù. ÇöÀç, ´ÜÀÏ ¿ä¹ýÀÌ ¼¼°è Fc/´ç¼â º¯Çü Ç×ü ½ÃÀå¿¡¼­ °¡Àå ³ôÀº ºñÀ²À» Â÷ÁöÇϰí ÀÖÁö¸¸, ÀÌ´Â ´ÜÀÏ ¿ä¹ý°ú °ü·ÃµÈ ¸î °¡Áö ÀåÁ¡, ¿¹¸¦ µé¾î ±ÔÁ¦ °æ·ÎÀÇ ¿ëÀ̼º, ÀáÀçÀû ¾à¹° »óÈ£ ÀÛ¿ë °¨¼Ò, ºñ¿ë È¿À²¼º µîÀÇ ÀåÁ¡ ¶§¹®ÀÔ´Ï´Ù.

Ä¡·á ¿µ¿ªº°·Î º¸¸é ½ÃÀåÀº ÀÚ°¡¸é¿ªÁúȯ, ÇǺÎÁúȯ, Á¾¾çÁúȯ, Èñ±ÍÁúȯ, ±âŸ ÁúȯÀ¸·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ¼¼°è Fc/´ç¼â º¯Çü Ç×ü ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ´Â ºÐ¾ß´Â Á¾¾ç Áúȯ ºÐ¾ßÀÔ´Ï´Ù. ±×·¯³ª ÀÚ°¡¸é¿ªÁúȯ ºÎ¹® ½ÃÀåÀº ¿¹Ãø ±â°£ Áß ´õ ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Åõ¿© °æ·Î¿¡ µû¶ó ½ÃÀåÀº Á¤¸Æ Åõ¿© °æ·Î, ÇÇÇÏ Åõ¿© °æ·Î, ±ÙÀ°³» Åõ¿© °æ·Î·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ¼¼°è Fc/´ç¼âº¯ÇüÇ×ü ½ÃÀåÀº Á¤¸ÆÅõ¿©¿ë Fc/´ç¼âº¯ÇüÇ×ü°¡ Áö¹èÀûÀÔ´Ï´Ù. ÀÌ´Â Á¤¸Æ Åõ¿©¸¦ ÅëÇØ Ç×ü°¡ Àü½Å¿¡ ºÐÆ÷ÇÏ¿© Ä¡·á È¿°ú¿Í »ýü ÀÌ¿ë·üÀÌ Çâ»óµÇ±â ¶§¹®ÀÔ´Ï´Ù.

ÁÖ¿ä Áö¿ªº°·Î ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ±âŸ Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù. ÇöÀç ºÏ¹Ì´Â ¼¼°è Fc Ç×ü ¹× ´ç¼â º¯Çü Ç×ü ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÇâÈÄ ´õ ³ôÀº CAGR·Î ¼ºÀåÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Fc ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀåÀÇ Âü¿© ±â¾÷ ¿¹

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °æÁ¦Àû ¹× ±âŸ ÇÁ·ÎÁ§Æ® ƯÀ¯ °í·Á »çÇ×

Á¦4Àå °³¿ä

Á¦5Àå ¼­·Ð

Á¦6Àå ½ÃÀå ±¸µµ

Á¦7Àå ±â¾÷ °³¿ä

Á¦8Àå ÀÓ»ó½ÃÇè ºÐ¼®

Á¦9Àå ÆÄÆ®³Ê½Ê°ú Çù¾÷

Á¦10Àå º¸Á¶±Ý ºÐ¼®

Á¦11Àå Æ¯Ç㠺м®

Á¦12Àå ¼¼°èÀÇ Fc °³º¯ ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå

Á¦13Àå Fc °³º¯ ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå(°³º¯ À¯Çüº°)

Á¦14Àå Fc °³º¯ ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå(Ä¡·á À¯Çüº°)

Á¦15Àå Fc °³º¯ ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå(Ä¡·á ¿µ¿ªº°)

Á¦16Àå Fc °³º¯ ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå(Åõ¿© °æ·Îº°)

Á¦17Àå Fc °³º¯ ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå(ÁÖ¿ä Áö¿ªº°)

Á¦18Àå Fc °³º¯ Ç×ü ¹× ´ç¼â °³º¯ Ç×ü ½ÃÀå, ÀǾàǰ ÆÇ¸Å ¿¹Ãø

Á¦19Àå °á·Ð

Á¦20Àå ºÎ·Ï I : Ç¥Çü½Ä µ¥ÀÌÅÍ

Á¦21Àå ºÎ·Ï II : ±â¾÷ ¹× Á¶Á÷ ¸®½ºÆ®

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

FC AND GLYCOENGINEERED ANTIBODIES MARKET: OVERVIEW

As per Roots Analysis, the global Fc and glycoengineered antibodies market is valued at USD 38.8 billion in the current year and is expected to grow at a lucrative CAGR during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Engineering

Type of Therapy

Therapeutic Area

Route of Administration

Key Geographical Regions

FC AND GLYCOENGINEERED ANTIBODIES MARKET: GROWTH AND TRENDS

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fastest growing segments of the biopharmaceutical industry. Further, within the antibody therapeutics industry, engineered antibodies, developed by modifying the fragment crystallizable (Fc) region, have garnered significant interest over the past few years. The modifications, such as glycoengineered antibodies, protein engineering or isotype chimerism in the Fc fusion protein of an antibody have shown to augment the various effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule. Moreover, several Fc engineering technologies enable the suppression of the effector functions in certain pathways and are being actively explored for development of anti-cancer antibodies.

Fc and Glycoengineered Antibodies Market - IMG1

The consistent research efforts in this domain have resulted into the emergence of two groundbreaking drugs, namely Gazyva (for Chronic Lymphocytic Leukemia) and POTELEGIO (for Sezary syndrome). Further, several other Fc engineered antibody products, including Margenza, MONJUVI and SKYRIZI have also received approval in the past few years. More recently, Fc engineered antibody, named Epcoritamab, received approval for the treatment of diffuse large B-cell lymphoma. Further, there are several drugs in the development pipeline, which are being investigated by various small and established pharmaceutical companies. With the promising clinical results coupled with ongoing technological developments, the market for Fc engineered antibodies is likely to evolve at a commendable pace over the next decade.

FC AND GLYCOENGINEERED ANTIBODIES MARKET: KEY INSIGHTS

The report delves into the current state of the Fc and glycoengineered antibodies market and identifies potential growth opportunities within industry. Some key findings from the report include:

Fc and Glycoengineered Antibodies Market - IMG2
Fc and Glycoengineered Antibodies Market - IMG3

FC AND GLYCOENGINEERED ANTIBODIES MARKET: KEY SEGMENTS

Fc Engineered Antibodies Segment holds the Largest Share of the Fc and Glycoengineered Antibodies Market

Based on the type of Fc engineering, the market is segmented into Fc engineered antibodies and glycoengineered antibodies. At present, the Fc engineered antibodies segment holds the maximum share of the global Fc and glycoengineered antibodies market. This trend is likely to remain the same in the coming years owing to the fact that Fc engineering enhances effector functions, improving the therapeutic efficacy of the modality.

By Type of Therapy, Monotherapy Segment Accounts for the Largest Share of the Global Fc and Glycoengineered Antibodies Market

Based on the type of therapy, the market is segmented into monotherapy, combination therapy and both. Currently, the monotherapy segment captures the highest proportion of the global Fc and glycoengineered antibodies market owing to the several benefits associated with monotherapy, such as easy regulatory pathways, reduced potential drug interactions and cost effectiveness.

By Therapeutic Area, Autoimmune Disorders is the Fastest Growing Segment of the Global Fc and Glycoengineered Antibodies Market

Based on the therapeutic area, the market is segmented into autoimmune disorders, dermatological disorders, oncological disorders, rare diseases and other disorders. At present, the oncological disorders segment holds the maximum share of the global Fc and glycoengineered antibodies market. However, the market for autoimmune disorders segment is expected to grow at a higher CAGR during the forecasted period.

The Intravenous Route Segment Account for the Largest Share of the Global Fc and Glycoengineered Antibodies Market

Based on the route of administration, the market is segmented into intravenous route, subcutaneous route and intramuscular route of administration. Currently, the global Fc and glycoengineered antibodies market is dominated by the Fc and glycoengineered antibodies for intravenous route of administration. This is due to the fact that intravenous route provides complete systemic distribution of antibodies facilitating enhanced therapeutic efficacy and bioavailability.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, North America dominates the global Fc and glycoengineered antibodies market and accounts for the largest revenue share. Further, the market Asia-Pacific is likely to grow at a higher CAGR in the coming future.

Example Players in the Fc and Glycoengineered Antibodies Market

FC AND GLYCOENGINEERED ANTIBODIES MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2 RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET LANDSCAPE

7. COMPANY PROFILES

8. CLINICAL TRIAL ANALYSIS

9. PARTNERSHIPS AND COLLABORATIONS

10. GRANT ANALYSIS

11. PATENT ANALYSIS

12. GLOBAL Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET

13. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF ENGINEERING

14. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY TYPE OF THERAPY

15. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY THERAPEUTIC AREA

16. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY ROUTE OF ADMINISTRATION

17. Fc ENGINEERED AND GLYCOENGINEERED ANTIBODIES MARKET, BY KEY GEOGRAPHICAL REGIONS

18. Fc ENGINEEREDAND GLYCOENGINEERED ANTIBODIES MARKET, SALES FORECAST OF DRUGS

19. CONCLUDING REMARKS

20 APPENDIX I: TABULATED DATA

21 APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â